165 related articles for article (PubMed ID: 20599429)
21. [Basic mechanisms of action of fingolimod in relation to multiple sclerosis].
García-Merino JA; Sánchez AJ
Rev Neurol; 2012 Jul; 55(1):31-7. PubMed ID: 22718407
[TBL] [Abstract][Full Text] [Related]
22. [New, effective immunomodulatory drug in treatment of multiple sclerosis: the fingolimod].
Komoly S
Ideggyogy Sz; 2012 Nov; 65(11-12):421-2. PubMed ID: 23289178
[No Abstract] [Full Text] [Related]
23. Fingolimod is a potential novel therapy for multiple sclerosis.
Aktas O; Küry P; Kieseier B; Hartung HP
Nat Rev Neurol; 2010 Jul; 6(7):373-82. PubMed ID: 20551946
[TBL] [Abstract][Full Text] [Related]
24. Fingolimod: a novel immunosuppressant for multiple sclerosis.
Brown BA; Kantesaria PP; McDevitt LM
Ann Pharmacother; 2007 Oct; 41(10):1660-8. PubMed ID: 17785617
[TBL] [Abstract][Full Text] [Related]
25. FTY720, a novel immunosuppressant, induces sequestration of circulating lymphocytes by acceleration of lymphocyte homing.
Chiba K; Yanagawa Y; Kataoka H; Kawaguchi T; Ohtsuki M; Hoshino Y
Transplant Proc; 1999; 31(1-2):1230-3. PubMed ID: 10083549
[No Abstract] [Full Text] [Related]
26. The impact of fingolimod (FTY720) in neuroimmunologic diseases: mechanisms beyond immunomodulation.
Haghikia A; Gold R
Am J Pathol; 2010 Jun; 176(6):2599-601. PubMed ID: 20395429
[TBL] [Abstract][Full Text] [Related]
27. FTY720 and central memory: out of sight, out of mind.
Slavin AJ; Zamvil SS
Neurology; 2010 Aug; 75(5):388-9. PubMed ID: 20610831
[No Abstract] [Full Text] [Related]
28. FTY720 (fingolimod) modulates the severity of viral-induced encephalomyelitis and demyelination.
Blanc CA; Rosen H; Lane TE
J Neuroinflammation; 2014 Aug; 11():138. PubMed ID: 25138356
[TBL] [Abstract][Full Text] [Related]
29. FTY720 impairs CD8 T-cell function independently of the sphingosine-1-phosphate pathway.
Ntranos A; Hall O; Robinson DP; Grishkan IV; Schott JT; Tosi DM; Klein SL; Calabresi PA; Gocke AR
J Neuroimmunol; 2014 May; 270(1-2):13-21. PubMed ID: 24680062
[TBL] [Abstract][Full Text] [Related]
30. FTY720: a most promising immunosuppressant modulating immune cell functions.
Zhang Z; Schluesener HJ
Mini Rev Med Chem; 2007 Aug; 7(8):845-50. PubMed ID: 17692046
[TBL] [Abstract][Full Text] [Related]
31. Overview and safety of fingolimod hydrochloride use in patients with multiple sclerosis.
Ward MD; Jones DE; Goldman MD
Expert Opin Drug Saf; 2014 Jul; 13(7):989-98. PubMed ID: 24935480
[TBL] [Abstract][Full Text] [Related]
32. Th17 central memory T cells are reduced by FTY720 in patients with multiple sclerosis.
Mehling M; Lindberg R; Raulf F; Kuhle J; Hess C; Kappos L; Brinkmann V
Neurology; 2010 Aug; 75(5):403-10. PubMed ID: 20592255
[TBL] [Abstract][Full Text] [Related]
33. Fingolimod for multiple sclerosis.
Pelletier D; Hafler DA
N Engl J Med; 2012 Jan; 366(4):339-47. PubMed ID: 22276823
[No Abstract] [Full Text] [Related]
34. Effects of different dose of FTY720 on lymphocyte cell cycle arrest in cardiac transplantation model of rats.
Li Q; Li F
Immunopharmacol Immunotoxicol; 2010 Dec; 32(4):680-7. PubMed ID: 20201753
[TBL] [Abstract][Full Text] [Related]
35. Reconstitution of the peripheral immune repertoire following withdrawal of fingolimod.
Ghadiri M; Fitz-Gerald L; Rezk A; Li R; Nyirenda M; Haegert D; Giacomini PS; Bar-Or A; Antel J
Mult Scler; 2017 Aug; 23(9):1225-1232. PubMed ID: 28749311
[TBL] [Abstract][Full Text] [Related]
36. Multiple sclerosis reactivation postfingolimod cessation: is it IRIS?
Alroughani R; Almulla A; Lamdhade S; Thussu A
BMJ Case Rep; 2014 Oct; 2014():. PubMed ID: 25320259
[TBL] [Abstract][Full Text] [Related]
37. Brain sphingosine-1-phosphate receptors: implication for FTY720 in the treatment of multiple sclerosis.
Dev KK; Mullershausen F; Mattes H; Kuhn RR; Bilbe G; Hoyer D; Mir A
Pharmacol Ther; 2008 Jan; 117(1):77-93. PubMed ID: 17961662
[TBL] [Abstract][Full Text] [Related]
38. Lymphocyte modulation with FTY720 improves hemorrhagic shock survival in swine.
Hawksworth JS; Graybill JC; Brown TS; Wallace SM; Davis TA; Tadaki DK; Elster EA
PLoS One; 2012; 7(4):e34224. PubMed ID: 22558085
[TBL] [Abstract][Full Text] [Related]
39. A novel immunosuppressant, FTY720, induces peripheral lymphodepletion of both T- and B cells and immunosuppression in baboons.
Quesniaux V; Fullard L; Arendse H; Davison G; Markgraaff N; Auer R; Ehrhart F; Kraus G; Schuurman HJ
Transpl Immunol; 1999 Sep; 7(3):149-57. PubMed ID: 10608298
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetic/pharmacodynamic relationships of FTY720 in kidney transplant recipients.
Park SI; Felipe CR; Machado PG; Garcia R; Skerjanec A; Schmouder R; Tedesco-Silva H; Medina-Pestana JO
Braz J Med Biol Res; 2005 May; 38(5):683-94. PubMed ID: 15917949
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]